palmidrol has been researched along with Pain in 42 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| ", PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced OA." | 7.85 | A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. ( Britti, D; Crupi, R; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Gugliandolo, E; Impellizzeri, D; Morittu, VM; Schievano, C, 2017) |
| " (1) The therapeutic effects of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide were tested in a model of persistent visceral pain (turpentine inflammation of the urinary bladder)." | 7.70 | The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. ( Hasnie, FS; Jaggar, SI; Rice, AS; Sellaturay, S, 1998) |
| " In inflamed bladders, URB937 had a U-shaped dose-response curve; following an initial cannabinoid receptor type 1-mediated reduction in pain responses and normalisation of bladder reflex activity, URB937 gradually increased both pain responses and bladder reflex activity through the transient receptor potential ion channel subfamily V member 1." | 5.56 | Fatty acid amide hydrolase inhibition normalises bladder function and reduces pain through normalising the anandamide/palmitoylethanolamine ratio in the inflamed bladder of rats. ( Charrua, A; Cruz, F; Marczylo, T; Matos, R; Nagy, I; Oliveira, R, 2020) |
| ", PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced OA." | 3.85 | A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. ( Britti, D; Crupi, R; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Gugliandolo, E; Impellizzeri, D; Morittu, VM; Schievano, C, 2017) |
| "The analgesic and anti-hyperalgesic effects of cannabinoid- and vanilloid-like compounds, plus the fatty acid amide hydrolase (FAAH) inhibitor Cyclohexylcarbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597), and acetaminophen, were evaluated in the phenyl-p-quinone (PPQ) pain model, using different routes of administration in combination with opioid and cannabinoid receptor antagonists." | 3.73 | Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. ( Cichewicz, DL; Haller, VL; Welch, SP, 2006) |
| "The potent analgesic effects of cannabis-like drugs and the presence of CB1-type cannabinoid receptors in pain-processing areas of the brain and spinal cord indicate that endogenous cannabinoids such as anandamide may contribute to the control of pain transmission within the central nervous system (CNS)." | 3.70 | Control of pain initiation by endogenous cannabinoids. ( Calignano, A; Giuffrida, A; La Rana, G; Piomelli, D, 1998) |
| " (1) The therapeutic effects of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide were tested in a model of persistent visceral pain (turpentine inflammation of the urinary bladder)." | 3.70 | The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. ( Hasnie, FS; Jaggar, SI; Rice, AS; Sellaturay, S, 1998) |
| "The aim of the study was to assess the safety, tolerability and efficacy of palmitoylethanolamide (PEA) when dosed at 300 mg and 600 mg per day on symptoms of knee osteoarthritis." | 2.90 | A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. ( Steels, E; Venkatesh, R; Vitetta, G; Vitetta, L, 2019) |
| " For treatment times up to 49 days, the current clinical data argue against serious adverse drug reactions (ADRs) at an incidence of 1/200 or greater." | 2.53 | Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. ( Fowler, CJ; Gabrielsson, L; Mattsson, S, 2016) |
| " Clinical trials are now required, but are hindered by a paucity of cannabinoids of suitable bioavailability and therapeutic ratio." | 2.41 | Cannabinoids and pain. ( Rice, AS, 2001) |
| " In inflamed bladders, URB937 had a U-shaped dose-response curve; following an initial cannabinoid receptor type 1-mediated reduction in pain responses and normalisation of bladder reflex activity, URB937 gradually increased both pain responses and bladder reflex activity through the transient receptor potential ion channel subfamily V member 1." | 1.56 | Fatty acid amide hydrolase inhibition normalises bladder function and reduces pain through normalising the anandamide/palmitoylethanolamine ratio in the inflamed bladder of rats. ( Charrua, A; Cruz, F; Marczylo, T; Matos, R; Nagy, I; Oliveira, R, 2020) |
| "The prevalence of idiopathic vulvodynia and proctodynia is high." | 1.40 | Vulvodynia and proctodynia treated with topical baclofen 5 % and palmitoylethanolamide. ( Keppel Hesselink, JM; Kopsky, DJ; Sajben, NL, 2014) |
| " The lipidic nature and large particle size of PEA in the native state may limit its solubility and bioavailability when given orally, however." | 1.40 | Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. ( Bruschetta, G; Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Impellizzeri, D; Siracusa, R, 2014) |
| "Effects of pre-treatment with a single dose, versus 4 day repeated dosing with the selective FAAH inhibitor, URB597 (i." | 1.38 | Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. ( Alexander, SP; Barrett, DA; Bennett, AJ; Burston, J; Chapman, V; Kendall, DA; Norris, LM; Okine, BN; Patel, A; Woodhams, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.76) | 18.2507 |
| 2000's | 9 (21.43) | 29.6817 |
| 2010's | 22 (52.38) | 24.3611 |
| 2020's | 9 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Lang-Illievich, K | 1 |
| Klivinyi, C | 1 |
| Rumpold-Seitlinger, G | 1 |
| Dorn, C | 1 |
| Bornemann-Cimenti, H | 1 |
| Toti, A | 1 |
| Micheli, L | 1 |
| Lucarini, E | 1 |
| Ferrara, V | 1 |
| Ciampi, C | 1 |
| Margiotta, F | 1 |
| Failli, P | 1 |
| Gomiero, C | 1 |
| Pallecchi, M | 1 |
| Bartolucci, G | 1 |
| Ghelardini, C | 1 |
| Di Cesare Mannelli, L | 1 |
| Huschtscha, Z | 1 |
| Fyfe, JJ | 1 |
| Feros, SA | 1 |
| Betik, AC | 1 |
| Shaw, CS | 1 |
| Main, LC | 1 |
| Abbott, G | 1 |
| Tan, SY | 1 |
| Refalo, MC | 1 |
| Gerhardy, M | 1 |
| Grunwald, E | 1 |
| May, A | 1 |
| Silver, J | 1 |
| Smith, CM | 1 |
| White, M | 1 |
| Hamilton, DL | 1 |
| Salaffi, F | 1 |
| Farah, S | 1 |
| Sarzi-Puttini, P | 1 |
| Di Carlo, M | 1 |
| Cuzzocrea, S | 8 |
| Crupi, R | 4 |
| Charrua, A | 1 |
| Matos, R | 1 |
| Oliveira, R | 1 |
| Marczylo, T | 1 |
| Nagy, I | 1 |
| Cruz, F | 1 |
| Petrosino, S | 3 |
| Schiano Moriello, A | 1 |
| Ardizzone, A | 1 |
| Fusco, R | 3 |
| Casili, G | 1 |
| Lanza, M | 1 |
| Impellizzeri, D | 4 |
| Esposito, E | 4 |
| Clayton, P | 1 |
| Hill, M | 1 |
| Bogoda, N | 1 |
| Subah, S | 1 |
| Venkatesh, R | 2 |
| Britti, D | 1 |
| Gugliandolo, E | 2 |
| Schievano, C | 1 |
| Morittu, VM | 1 |
| Evangelista, M | 2 |
| Di Paola, R | 2 |
| Gorelik, A | 1 |
| Gebai, A | 1 |
| Illes, K | 1 |
| Piomelli, D | 5 |
| Nagar, B | 1 |
| Aldossary, SA | 1 |
| Alsalem, M | 1 |
| Kalbouneh, H | 1 |
| Haddad, M | 1 |
| Azab, B | 1 |
| Al-Shboul, O | 1 |
| Mustafa, AG | 1 |
| Obiedat, S | 1 |
| El-Salem, K | 1 |
| Steels, E | 2 |
| Vitetta, G | 1 |
| Vitetta, L | 1 |
| Zhou, P | 1 |
| Xiang, L | 1 |
| Yang, Y | 1 |
| Wu, Y | 1 |
| Hu, T | 1 |
| Liu, X | 1 |
| Lin, F | 1 |
| Xiu, Y | 1 |
| Wu, K | 1 |
| Lu, C | 1 |
| Ren, J | 1 |
| Qiu, Y | 1 |
| Li, Y | 1 |
| Davis, MP | 1 |
| Behm, B | 1 |
| Mehta, Z | 1 |
| Fernandez, C | 1 |
| Peritore, AF | 1 |
| Cordaro, M | 2 |
| Siracusa, R | 2 |
| D'Amico, R | 1 |
| Descalzi, F | 1 |
| Ulivi, V | 1 |
| Cancedda, R | 1 |
| Piscitelli, F | 1 |
| Luongo, L | 1 |
| Guida, F | 1 |
| Gatta, L | 1 |
| Maione, S | 1 |
| Di Marzo, V | 4 |
| Keppel Hesselink, JM | 1 |
| Kopsky, DJ | 1 |
| Sajben, NL | 1 |
| Mattace Raso, G | 1 |
| Russo, R | 2 |
| Calignano, A | 5 |
| Meli, R | 2 |
| Bruschetta, G | 1 |
| Koltyn, KF | 1 |
| Brellenthin, AG | 1 |
| Cook, DB | 1 |
| Sehgal, N | 1 |
| Hillard, C | 1 |
| Ahmad, A | 1 |
| Marcolongo, G | 1 |
| Allarà, M | 1 |
| Verde, R | 1 |
| Donvito, G | 1 |
| Bettoni, I | 1 |
| Comelli, F | 1 |
| Colombo, A | 1 |
| Costa, B | 1 |
| Gabrielsson, L | 1 |
| Mattsson, S | 1 |
| Fowler, CJ | 1 |
| Okine, BN | 2 |
| Madasu, MK | 1 |
| McGowan, F | 1 |
| Prendergast, C | 1 |
| Gaspar, JC | 1 |
| Harhen, B | 1 |
| Roche, M | 1 |
| Finn, DP | 1 |
| Loría, F | 1 |
| Mestre, L | 1 |
| Spagnolo, A | 1 |
| Correa, F | 1 |
| Hernangómez, M | 1 |
| Guaza, C | 1 |
| Docagne, F | 1 |
| Karbarz, MJ | 1 |
| Luo, L | 1 |
| Chang, L | 1 |
| Tham, CS | 1 |
| Palmer, JA | 1 |
| Wilson, SJ | 1 |
| Wennerholm, ML | 1 |
| Brown, SM | 1 |
| Scott, BP | 1 |
| Apodaca, RL | 1 |
| Keith, JM | 1 |
| Wu, J | 1 |
| Breitenbucher, JG | 1 |
| Chaplan, SR | 1 |
| Webb, M | 1 |
| Sasso, O | 1 |
| Vitiello, S | 1 |
| Raso, GM | 1 |
| D'Agostino, G | 1 |
| Iacono, A | 1 |
| La Rana, G | 4 |
| Vallée, M | 1 |
| Piazza, PV | 1 |
| Naderi, N | 1 |
| Majidi, M | 1 |
| Mousavi, Z | 1 |
| Khoramian Tusi, S | 1 |
| Mansouri, Z | 1 |
| Khodagholi, F | 1 |
| Truini, A | 1 |
| Biasiotta, A | 1 |
| Di Stefano, G | 1 |
| La Cesa, S | 1 |
| Leone, C | 1 |
| Cartoni, C | 1 |
| Federico, V | 1 |
| Petrucci, MT | 1 |
| Cruccu, G | 1 |
| Norris, LM | 1 |
| Woodhams, S | 1 |
| Burston, J | 1 |
| Patel, A | 1 |
| Alexander, SP | 1 |
| Barrett, DA | 1 |
| Kendall, DA | 1 |
| Bennett, AJ | 1 |
| Chapman, V | 1 |
| Re, G | 1 |
| Barbero, R | 1 |
| Miolo, A | 1 |
| Breathnach, R | 1 |
| Haller, VL | 1 |
| Cichewicz, DL | 1 |
| Welch, SP | 1 |
| Wallace, VC | 1 |
| Segerdahl, AR | 1 |
| Lambert, DM | 1 |
| Vandevoorde, S | 1 |
| Blackbeard, J | 1 |
| Pheby, T | 1 |
| Hasnie, F | 1 |
| Rice, AS | 3 |
| Giuffrida, A | 1 |
| Jaggar, SI | 1 |
| Hasnie, FS | 1 |
| Sellaturay, S | 1 |
| Loubet-Lescoulié, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Postoperative Pain and Inflammation Following Below Knee Fracture Fixation: A Pilot Study.[NCT05317676] | Phase 2 | 0 participants (Actual) | Interventional | 2023-05-31 | Withdrawn (stopped due to Sponsor suspending temporarily.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for palmidrol and Pain
| Article | Year |
|---|---|
Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries-A Systematic Review.
Topics: Alzheimer Disease; Amides; Amyotrophic Lateral Sclerosis; Animals; Autism Spectrum Disorder; Endocan | 2020 |
Palmitoylethanolamide: A Natural Compound for Health Management.
Topics: Amides; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Dietary Suppleme | 2021 |
The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review.
Topics: Amides; Animals; Ethanolamines; Humans; Mental Disorders; Neurodegenerative Diseases; Pain; Palmitic | 2019 |
Palmitoylethanolamide in CNS health and disease.
Topics: Amides; Animals; Anti-Inflammatory Agents; Central Nervous System; Ethanolamines; Humans; Inflammati | 2014 |
Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy.
Topics: Amides; Analgesics; Ethanolamines; Humans; Pain; Palmitic Acids | 2016 |
Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma.
Topics: Amides; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Endocannabinoids; Ethanolamine | 2013 |
Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals.
Topics: Amides; Analgesics; Animals; Cannabinoids; Endocannabinoids; Ethanolamines; Inflammation; Pain; Palm | 2007 |
A role for the endogenous cannabinoid system in the peripheral control of pain initiation.
Topics: Amides; Analgesics; Animals; Arachidonic Acids; Brain; Cannabinoids; Drug Interactions; Endocannabin | 2000 |
Cannabinoids and pain.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Benzoxazines; Brain; Camphanes; Can | 2001 |
5 trials available for palmidrol and Pain
| Article | Year |
|---|---|
The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial.
Topics: Amides; Analgesics; Anti-Inflammatory Agents; Cross-Over Studies; Double-Blind Method; Ethanolamines | 2022 |
A randomised controlled trial assessing the potential of palmitoylethanolamide (PEA) to act as an adjuvant to resistance training in healthy adults: a study protocol.
Topics: Adolescent; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Australia; Dietary Supplemen | 2023 |
Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study.
Topics: Acetylcarnitine; Analgesics; Duloxetine Hydrochloride; Fibromyalgia; Humans; Pain; Pregabalin; Treat | 2023 |
A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis.
Topics: Adult; Aged; Amides; Anti-Inflammatory Agents, Non-Steroidal; Depressive Disorder, Major; Double-Bli | 2019 |
Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy.
Topics: Aged; Aged, 80 and over; Amides; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; End | 2011 |
28 other studies available for palmidrol and Pain
| Article | Year |
|---|---|
Ultramicronized
Topics: Analgesics, Opioid; Astrocytes; Drug Tolerance; Humans; Mast Cells; Morphine; Pain | 2023 |
To Go Where Nature Leads: Focus on Palmitoylethanolamide and Related ALIAmides as Innovative Approach to Neuroinflammatory and Pain-Related Disease States in Honor of Doctor Francesco Della Valle.
Topics: Amides; Ethanolamines; Humans; Pain; Palmitic Acids | 2023 |
Fatty acid amide hydrolase inhibition normalises bladder function and reduces pain through normalising the anandamide/palmitoylethanolamine ratio in the inflamed bladder of rats.
Topics: Amides; Amidohydrolases; Animals; Arachidonic Acids; Cannabinoids; Cystitis; Endocannabinoids; Ethan | 2020 |
Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain.
Topics: Acetylcarnitine; Amides; Animals; Carrageenan; Cell Count; Cyclooxygenase 2; Disease Models, Animal; | 2021 |
A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models.
Topics: Administration, Oral; Amides; Animals; Anti-Inflammatory Agents; Carrageenan; Drug Combinations; Ede | 2017 |
Molecular mechanism of activation of the immunoregulatory amidase NAAA.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Catalytic Domain; Cell Line; Drug Discovery; Enzyme In | 2018 |
The role of transient receptor potential vanilloid receptor 1 and peroxisome proliferator-activated receptors-α in mediating the antinociceptive effects of palmitoylethanolamine in rats.
Topics: Amides; Analgesics; Animals; Disease Models, Animal; Ethanolamines; Ganglia, Spinal; Male; Nocicepti | 2019 |
N-Acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritis.
Topics: Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents; Cartilage; Cells, Cultured; Chondrocytes | 2019 |
The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice.
Topics: Amides; Analgesics; Animals; Anti-Inflammatory Agents; Apoptosis; Cytokines; Diabetic Neuropathies; | 2019 |
Platelet-rich plasma exerts antinociceptive activity by a peripheral endocannabinoid-related mechanism.
Topics: Amides; Analgesics; Animals; Arachidonic Acids; Blotting, Western; Cell Line, Tumor; Endocannabinoid | 2013 |
Vulvodynia and proctodynia treated with topical baclofen 5 % and palmitoylethanolamide.
Topics: Administration, Topical; Adult; Amides; Anti-Inflammatory Agents, Non-Steroidal; Anus Diseases; Bacl | 2014 |
Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.
Topics: Administration, Oral; Amides; Analgesics; Animals; Carrageenan; Chemistry, Pharmaceutical; Chromatog | 2014 |
Mechanisms of exercise-induced hypoalgesia.
Topics: Adolescent; Adult; Amides; Arachidonic Acids; Cross-Over Studies; Double-Blind Method; Endocannabino | 2014 |
Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Anthraquinones; Anti-Inflammatory Agents; Carrageenan; | 2015 |
Palmitoylethanolamide relieves pain and preserves pancreatic islet cells in a murine model of diabetes.
Topics: Amides; Analgesics; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Ethanolamines; | 2015 |
N-palmitoylethanolamide in the anterior cingulate cortex attenuates inflammatory pain behaviour indirectly via a CB1 receptor-mediated mechanism.
Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cannabinoid Receptor Antagonists; Cohort S | 2016 |
Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide.
Topics: Amides; Animals; Anti-Inflammatory Agents; Antiviral Agents; Cannabinoid Receptor Modulators; Cytoki | 2008 |
Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Brain; Carrageenan; Disease Models, | 2009 |
Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain.
Topics: Amides; Analgesics; Animals; Endocannabinoids; Ethanolamines; Hyperalgesia; Male; Mice; Pain; Pain M | 2012 |
A thickening network of lipids.
Topics: Amides; Analgesics; Animals; Endocannabinoids; Ethanolamines; Male; Pain; Palmitic Acids; Pregnanolo | 2012 |
The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-β expression in rats.
Topics: Amides; Animals; Drug Interactions; Endocannabinoids; Ethanolamines; Injections, Spinal; Interleukin | 2012 |
Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system.
Topics: Amides; Amidohydrolases; Animals; Arachidonic Acids; Behavior, Animal; Benzamides; Carbamates; Disea | 2012 |
The psychedelic haze of inflammation.
Topics: Amides; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cannabinoids; Endocann | 2007 |
Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Topics: Acetaminophen; Amides; Analgesics; Animals; Arachidonic Acids; Benzamides; Benzoquinones; Camphanes; | 2006 |
The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy.
Topics: Amides; Amines; Animals; Behavior, Animal; Camphanes; Cyclohexanecarboxylic Acids; Dose-Response Rel | 2007 |
Control of pain initiation by endogenous cannabinoids.
Topics: Amides; Analgesics; Animals; Arachidonic Acids; Cannabinoids; Drug Synergism; Endocannabinoids; Etha | 1998 |
The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain.
Topics: Amides; Analgesics; Animals; Arachidonic Acids; Cannabinoids; Capillary Permeability; Cystitis; Elec | 1998 |
Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide.
Topics: Amides; Analgesics; Analysis of Variance; Animals; Arachidonic Acids; Calcium Channel Blockers; Camp | 2001 |